Saikosaponin A, a natural product isolated and purified from the root of Bupleurum chinense DC., with antioxidant activity, has an inhibitory activity against allergic asthma and an anti-inflammatory activity by inhibiting the MAPK andNF-κB pathways in LPS-stimulated RAW 264.7 cells, shows the most potent cytotoxicity against human cancer cells, and is an inhibitory for cell growth and DNA synthesis with 50-μg/mL.
Saikosaponin A (SSA), a main triterpenoid saponin component from Radix Bupleurum, has been revealed to have a variety of pharmacological activities. SSA can suppress angiogenesis and tumor growth by blocking the VEGFR2-mediated signaling pathway[3]. SSa (Saikosaponin A) inhibited IL-1β-induced PGE2 and NO production in a concentration-dependent manner. SSa also suppressed IL-1β-induced MMP1, MMP3, and MMP13 production. Furthermore, SSa significantly attenuated IL-1β-induced phosphorylation levels of NF-κB p65 and IκBα. SSa also up-regulated the expression of LXRα. The inhibition of SSa on PGE2, NO, MMP1, MMP3, and MMP13 production were reversed by LXRα siRNA or GGPP, the inhibitor of LXRα[4]. SSa played a critical anti-inflammatory effect through inhibition of NF-κB and NLRP3 signaling pathways and protected against LPS-induced ALI(acute lung injury)[5]. Saikosaponin A had protective effects against DSS (dextran sulfate sodium)-induced colitis. Saikosaponin A protected DSS-induced colitis through inhibiting inflammatory response[6].
搜索
